Online inquiry

IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6283MR)

This product GTTS-WQ6283MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Cancers, non-small cell lung (NSCLC), T cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6283MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15220MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ7618MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ11341MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ10325MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ8902MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ1010MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-383
GTTS-WQ4987MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ10807MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW